key: cord-0720373-4y753m1t
authors: Vicinanza, Carla; Lombardi, Elisabetta; Da Ros, Francesco; Marangon, Miriam; Durante, Cristina; Mazzucato, Mario; Agostini, Francesco
title: Modified mesenchymal stem cells in cancer therapy: A smart weapon requiring upgrades for wider clinical applications
date: 2022-01-26
journal: World J Stem Cells
DOI: 10.4252/wjsc.v14.i1.54
sha: 94d9fd4140ca38501b9a4b9c916a17f42d6baf6c
doc_id: 720373
cord_uid: 4y753m1t

Mesenchymal stem stromal cells (MSC) are characterized by the intriguing capacity to home toward cancer cells after systemic administration. Thus, MSC can be harnessed as targeted delivery vehicles of cytotoxic agents against tumors. In cancer patients, MSC based advanced cellular therapies were shown to be safe but their clinical efficacy was limited. Indeed, the amount of systemically infused MSC actually homing to human cancer masses is insufficient to reduce tumor growth. Moreover, induction of an unequivocal anticancer cytotoxic phenotype in expanded MSC is necessary to achieve significant therapeutic efficacy. Ex vivo cell modifications are, thus, required to improve anti-cancer properties of MSC. MSC based cellular therapy products must be handled in compliance with good manufacturing practice (GMP) guidelines. In the present review we include MSC-improving manipulation approaches that, even though actually tested at preclinical level, could be compatible with GMP guidelines. In particular, we describe possible approaches to improve MSC homing on cancer, including genetic engineering, membrane modification and cytokine priming. Similarly, we discuss appropriate modalities aimed at inducing a marked cytotoxic phenotype in expanded MSC by direct chemotherapeutic drug loading or by genetic methods. In conclusion, we suggest that, to configure MSC as a powerful weapon against cancer, combinations of clinical grade compatible modification protocols that are currently selected, should be introduced in the final product. Highly standardized cancer clinical trials are required to test the efficacy of ameliorated MSC based cell therapies.

In multicellular organisms, continuous regeneration and functional maintenance of adult tissues are assured by a stem cell reservoir. The word "stem" is derived, in fact, from the Latin stamen, i.e., the warp thread composing a tissue. In the early 70s Friedenstein et al [1, 2] identified, within the bone marrow, rare multipotent nonhematopoietic fibroblast-like cells characterized by the capacity to differentiate into osteoblasts. As previously reviewed [3] , such mesenchymal precursors of stromal cells were shown to play a crucial role in hematopoietic stem cell differentiation and maintenance within the bone marrow niche. In light of their capacity to differentiate into chondrocytes and adipocytes and bone osteocytes[4,5] they were named mesenchymal stem cells [6] . In a position statement of the International Society for Cell Therapies, the definition of such cells was further improved to multipotent mesenchymal stem stromal cells (MSC) [7] . In the same work, the International Society for Cell Therapies proposed three criteria to define MSC. Adherence to a tissue culture plastic substrate is the first mandatory condition for MSC expansion in standard culture medium. A second requirement, flow cytometry analysis must demonstrate that at least 95% of expanded cells express CD105, CD73 and CD90 and that less than 2% express CD45, CD34, CD14 or CD11b, CD79a or CD19 and human leukocyte antigen class II. Finally, MSC must show the above-mentioned tri-lineage differentiation capacity into chon-drocytes, adipocytes and osteocytes.

MSC can be derived from virtually all post-natal human tissues[8] with different abundances. Perinatal tissues such as amniotic fluid [9] , umbilical cord blood[10] and Wharton jelly [11] are considered relevant sources of MSC. Precursors are very rare in adult circulating blood [12] , while adipose mesenchymal stem cells (ASC) are particularly abundant in fat tissue [13] .

In a previously published seminal work, induced pluripotent stem cells (iPSC) were obtained by reprogramming differentiated human somatic cells through artificial introduction of multiple genes and the same work showed that iPSC were characterized by the capacity to induce teratomas in vivo [14] . Plating iPSC and sorting cells by expression of selected cell surface markers allowed successful isolation of cells meeting minimal criteria to be defined as MSC [15] .

In this review, we focus on MSC related applications as an advanced therapeutic tool against cancer. General MSC biological properties are summarized, but relevant features motivating the choice of MSC as a potential tool against tumor progression are emphasized. Manipulation of cellular therapy products for application in human patients must be performed in compliance with strict regulations warranting safety and efficacy. Thus, we describe published strategies aimed at improving MSC anticancer action, choosing approaches that we consider to be potentially compatible with clinical grade production guidelines and regulatory limitations.

In addition to their regenerative potential, MSC as well as iPSC derived MSC, can efficiently modulate reactivity of the recipient immune system mainly acting as suppressing agents [21, 22] . MSC mediated immune regulation was shown to be dependent on microenvironmental cues [21, 23] : In particular, MSC exposure to a low grade inflammatory milieu was shown, in murine models, to enhance inflammatory processes such as monocyte mobilization [24] . Such an MSC mediated effect was shown to be determined by secretion of specific chemokines, in turn recruiting lymphocytes [25] . As characterized in the literature [26] , MSC exposure to elevated concentrations of proinflammatory mediators (licensing) can trigger their anti-inflammatory properties [25] . Coculturing MSC with monocytes, after application of sufficient pro-inflammatory stimuli, was shown to promote polarization of macrophages to the anti-inflammatory M2 phenotype [27] . Similarly, expanded MSC were shown to induce in culture a regulatory T cell phenotype in CD4+ cells [28] . Moreover, previous works reported that appropriate MSC licensing by stimulatory cytokines, such as interferon gamma (IFN-γ) together with tumor necrosis factor alpha (TNF-α) can properly stimulate and enhance their capacity to downregulate inflammation[26].

As previously reviewed [29] , MSC are characterized by the peculiar capacity to spontaneously reach damaged or inflamed tissues as well as primary or metastatic cancer masses (Figure 1 ). Although not fully elucidated, mechanisms regulating such processes are analogous to the leukocyte model of adhesion and invasion [30] . When in contact with endothelial cells within an inflamed microenvironment, circulating MSC can set transient and repeated physical interactions, resulting in cell tethering and rolling: This represents a crucial and rate limiting step in the cell adhesion process [29, 30] . Selectin expression on the endothelial surface is known to mediate leukocyte tethering and rolling on the internal vessel lumen [31] . Accordingly, MSC can bind in vitro and in vivo selectins expressed on inflamed endothelial cells [32] . The capacity of MSC to interact with the endothelium through selectins, was questioned: MSC were, in fact, shown not to normally express the P-selectin glycoprotein ligand-1 containing the active interaction domain Sialyl Lewis X (SLeX) [33] [34] [35] . Further investigations are required to fully clarify mechanisms explaining MSC early interaction with inflamed endothelial cells.

Following loose contacts with endothelial cells, MSC activation can trigger firm cell adhesion. This process is mainly mediated by the interaction between stromal derived factor-1 (SDF-1), a ligand expressed on endothelial cells, and the C-X-C chemokine receptor type 4 (CXCR4) exposed on MSC [36] . In a clinical trial testing the efficacy of modified MSC against glioblastoma, the authors showed that migration capacities and expression levels of selected adhesion molecules (e.g., CXCR1 and CXCR4) were higher in MSC derived from responding patients vs non-responders [37] . MSC activation by chemokine interaction with the receptor can fully stabilize cell adhesion, increasing integrin affinity for extracellular matrix proteins or for other adhesion molecules [38] [39] [40] . In particular, SDF-1 interaction with CXCR4 can activate integrins such as very late antigen-4 (VLA-4), in turn promoting MSC adhesion through vascular cell adhesion molecule 1 (VCAM-1) [ Firmly adhering MSC can extravasate crossing the inflamed endothelium mainly through paracellular and transcellular diapedesis [41] . Inflammation elicited activation and secretion of metalloproteases (MMP) plays a crucial role in this step, paving the way to final interstitial migration toward the target site [41, 43] . Together with CXCR4, MMP-2 is involved in MSC tropism to subcutaneous and lung metastatic prostate tumors in vitro [44] .

Final MSC migration toward the target site occurs in response to various and poorly defined chemotactic stimuli released by inflamed tissues. Interaction between CXCR4 and SDF-1 was proven to be important for MSC final nesting within bone marrow [ 

As previously mentioned, MSC precursors can be obtained from different human source tissues such as bone marrow, adipose tissue, cord blood or Wharton jelly. Upon isolation, the absolute number of cells is not sufficient for clinical applications in humans. To obtain a sufficient amount of cells to be administered as an autologous or allogenic Advanced Cell Therapy Product, ex vivo cell expansion is mandatory. When intended for therapeutic applications, MSC must be isolated and cultured in accordance with good manufacturing practice (GMP) rules for medicinal products (European Cgmp-Annex 1: Manufacture of sterile medicinal products). For this reason, procedures must be performed in appropriate facilities allowing strict control of environmental air quality. Contamination levels of environments are classified from the cleanest "A" to "D". Authorized personnel can progressively access from external not-classified areas to class "B" operational rooms wearing disposable sterile coats. Class "A" air contamination level is obtained by taking advantage of a sterile laminar flow biological cabinet that must be located within the class B environment. Maintenance of air quality within defined standards is obtained by setting positive pressure differences between the highest and lowest classified areas. Rigorous environmental microbiological tests must be routinely performed to demonstrate compliance with required standards. The cell product must be manipulated with validated procedures and standardized quality control tests must be carried out in order to warrant product safety, identity and compliance with intended use[62,63]. Only GMP certified devices, disposables and growth media can be used within the production pipeline. Reagents and additives must be non-toxic, highly standardized, and they must not contain animal derived components (European cGMP-Annex 1: Manufacture of sterile medicinal products). The final product can be "released" for human applications, only after approval by an authorized Qualified Person, carefully checking full compliance with defined requirements and standards. In a recently published work, we focused on the identification of a substitute for fetal bovine serum, as a source of growth factors to promote cell expansion[64]: The adoption of such an animal derived additive is, in fact, not recommended for GMP compliant cell therapy production protocols. We took advantage of a supernatant rich in growth factors (SRGF) derived from a platelet apheresis product [65] in which the coagulation cascade was triggered by the addition of a standardized concentration of CaCl 2 . We previously demonstrated that SRGF is characterized by elevated concentrations of crucial growth factors involved in cell cycle progression such as platelet derived growth factor isoforms AA, AB, and BB, as well as epidermal growth factor and fibroblast growth factor [64] . SRGF was shown to increase, when compared to fetal bovine serum, the proliferation rate of ASC also at extended passages, without affecting cell phenotype, differentiation and clonogenic potential, as well as karyotype stability [64] . Of note, by exposing ASC to a medium containing 5% SRGF we obtained in less than two weeks the same cell yield reached when expanding cells for two months in the presence of 10% fetal bovine serum. Growth factor concentrates derived from platelets can also be obtained by other means e.g., repeated freeze and thaw cycles to disrupt platelet cell membranes, and such a platelet lysate was previously shown to efficiently surrogate fetal bovine serum in GMP compliant culture [66] . We also demonstrated that, when compared to a platelet lysate, SRGF induced a higher bone marrow MSC proliferation rate: This effect was reasonably shown to be mediated by increased platelet derived growth factor concentrations in SRGF [67] . As previously mentioned, standardization of ancillary medium additives is fundamental for GMP guidelines in order to warrant a safe and consistent product expansion. Pooling together single donor derived platelet products can efficiently minimize biological variability between medium additive batches[68], but the definition of the optimal pool size is not trivial, especially for academic GMP facilities. We demonstrated that to January 26, 2022 Volume 14 Issue 1 obtain stable SRGF batches, that equally stimulate MSC proliferation rate, at least 16 different SRGF products derived from single donors must be mixed together[69]: To achieve this aim, we adopted a predictive mathematical approach, followed by "wet biology" validation. In order to identify, in compliance with GMP requirements, a reliable and comprehensive quality control assay for SRGF, we manufactured from platelet concentrates several medium additive types differently promoting ASC growth rate [70] . Interestingly, while integrative analysis of growth factor concentration changes was shown to be insufficiently sensitive, 1 H-NMR and MALDI-TOF MS could clearly identify differences between product isoforms. Thus, we concluded that a single analysis using such metabolomic approaches could rapidly predict and classify the potential biological activity of our GMP compatible ancillary product. Thus, the exact involvement of CXCR4 in MSC migration toward cancer cells was not univocally clarified. Identification of selected homing controlling factors, whose nonviral overexpression could improve MSC targeting to cancer masses, could simplify the GMP compliant obtainment of a cell product with ameliorated therapeutic effectiveness.

Specific targeting or adhesion moieties can be added, by different means, to the cell membrane of expanded MSC. In principle, using certified reagents and performing an appropriate product validation, membrane modification can be performed in compliance with GMP guidelines. As mentioned above, selectin mediated rolling is a crucial and rate limiting step in the cell adhesion process [31, 33] . In order to increase the fraction of rolling cells in dynamic conditions, in a seminal work by Sackstein et al [34] , the normally expressed CD44 antigen on MSC was converted, by alpha-1,3fucosyltransferase, to E-selectin/L-selectin ligand (HCELL), which is expressed in bone marrow hematopoietic stem cells. In addition, HCELL over expression increased MSC trans-endothelial migration [87] . Furthermore, covalent modifications or lipidic particles addition were adopted[35] to load biotin on the MSC cell surface, as a docking site for specific streptavidin-bound ligands: Using such strategies, MSC were decorated with the active integrin binding factor SLeX to improve cell-substrate interaction in in vitro dynamic flow conditions. Furthermore, palmitated protein A/G as well as bi-specific antibodies were used to enrich MSC membranes with specific antigens or receptors improving the migratory properties of MSC [88] . Palmitic acid conjugated peptides can be easily coated on MSC membranes to tailor their homing potential[89,90]. To our knowledge, even though deserving investigation, the efficacy of such cell membrane modification protocols has not yet been tested as a strategy to improve the fraction of MSC selectively homing to cancer.

As mentioned above, MSC behavior can be modulated by the so called "licensing" approach, i.e., cell exposure to selected cytokine(s) in culture. This simple approach was included in the present review as, running appropriate validation and quality controls, it could be easily translated to production processes under GMP guidelines. MSC priming was previously investigated to direct cells toward a sharp anti-inflammatory phenotype[26] and can be applied to tailor and ameliorate general migration and homing properties of MSC. Incubating MSC in the presence of appropriate TNF-α concentrations can, in fact, trigger the enhanced expression of CXCR4[91], in turn potentially ameliorating the homing efficiency of such cells. MSC pre-exposure to TNF-α was also shown to improve MSC adhesion to endothelial cells in vitro and in rat ischemic hind limbs, through upregulation of VCAM-1[92]. Similarly, TNF-α preconditioned MSC could better migrate in vitro toward selected chemokines such as the above-mentioned SDF-1, but this effect could not be correlated to CXCR4 expression levels [93] . In parallel, migration of MSC was also shown to be enhanced by exposure to transforming growth factor beta (TGF-β) [ , the authors demonstrated that transient exposure of MSC to conditioned medium from glioma cells increased MSC migration potential toward glioblastoma itself, both in vitro (static and microfluidic conditions) and in vivo (mouse model). In the same work, the authors showed that the conditioned medium contained higher levels of IFN-γ, IL-6, IL-8 and TNF-α.

In addition, preventive exposure of MSC to valproic acid[104], as well as to erythropoietin and granulocyte colony-stimulating factor[105] was shown to ameliorate their homing properties toward inflamed tissues. Finally, culturing MSC in hypoxic conditions increased the number of migrating MSC as a consequence of hypoxia inducible factor-1α and SDF-1 overexpression [106] . The aforementioned evidence suggests that appropriately priming MSC in culture can improve their capacity to reach inflamed tissues after systemic administration. Considering cancer as a never-healing wound that secretes inflammatory cytokines and chemotactic factors ( e.g., monocyte chemotactic protein-1, SDF-1, TGF-β, TNF-α, ILs), MSC licensing can be considered a potentially GMP compatible and simple option to improve MSC homing toward tumor masses [107, 108] .

We recently demonstrated that modification of culture conditions can improve ASC homing properties in vitro: We showed that, when compared to fetal bovine serum expanded MSC, SRGF cultured cells could better adhere in microfluidic conditions on a layer of fibrosarcoma (HT1080) or glioblastoma (T98G) cells [109] . Cell interaction with selected cancer tissues was shown to be specific because MSC expanded using SRGF additive displayed lower affinity for hepatocarcinoma cells and for unspecific interaction sites, i.e., mixed extracellular matrix proteins [109] . We also showed that cell activation, evidenced by intracellular calcium concentration changes, occurred upon the adhesion of SRGF expanded ASC on cancer cells and extracellular matrix proteins [109]. [118] . Interestingly, in a previous paper, iPSC derived MSCs, when compared to adult bone marrow MSC, were characterized by a weaker capacity to promote cancer cell growth and invasion in vitro [119] . On the other hand, unmodified MSC were also shown to actively counteract cancer expansion. In particular, MSC were demonstrated to induce cell cycle arrest in hepatoma cells in vitro and in vivo, promoting p21 expression[120] and such cells were shown to trigger apoptosis through caspase-3 and caspase-9 induction in cancer cells [121] . When expanded at high density, MSC overexpressed IFN-β, which directly induced in vitro breast cancer cell death [122] . In an attempt to apply MSC as a therapeutic tool against cancer, such a potentially bivalent role toward tumor cells must be clearly overcome, by introducing appropriate cell modifications that confer an unequivocal on-target cytotoxic behavior. In the following sections, we will discuss selected approaches to modify MSC that, in principle, could rapidly be translated to clinical applications, following GMP rules.

After transient exposure in culture vessels, MSC can uptake chemotherapeutic drugs such as doxorubicin, paclitaxel, or gemcitabine[123]. Following drug removal, MSC can locally release their payload by passive diffusion, and exosome secretion[124] in turn inducing cancer cell death. Thus, after migration and homing toward cancer cells, MSC can release active substances in the tumor stroma, inducing localized cancer cytolysis.

Doxorubicin loaded MSC were effective against breast and thyroid cancer in vitro and in vivo in mice [125] as well as in counteracting oral squamous cell carcinoma [126] . MSC exposure to nanoparticles with adsorbed doxorubicin was adopted as a strategy to control drug release: Such an approach was effective in reducing the proliferation of breast cancer, lung melanoma metastasis and glioblastoma in mice [127, 128] . Purified exosomes obtained from doxorubicin loaded MSC were shown to be a potentially effective cell-free targeted therapy against osteosarcoma cells [129] . Furthermore, linking doxorubicin-loaded liposomes on MSC outer membranes, a specific cytotoxic effect against colon adenocarcinoma was observed in vitro and in mice, with a limited impact on MSC as carrier cells [130] .

Paclitaxel loaded MSC were shown to be effective against pancreatic [131] and brain cancer [132] , as well as squamous cell carcinoma [126] , mesothelioma [133] , metastatic lung cancer[47] and leukemia [134] . In a recent work[135], drug pharmacokinetics and pharmacodynamics after administration of MSC containing paclitaxel loaded nanoparticles were analyzed, and the authors demonstrated that mouse orthotopic human lung tumors were completely eradicated after administration of 2 × 10 6 MSC January 26, 2022

Volume 14 Issue 1 (equivalent to 50 µg or 2.5 mg/kg of paclitaxel). In analogy, MSC containing paclitaxel loaded nanoparticles were shown in vitro and in vivo to be a promising treatment for glioma and lung carcinoma targeted therapy [136, 137] . Moreover, functionalization of MSC cell membranes with a transcription activating peptide, improved intracellular accumulation of nanoparticles in MSC as well as paclitaxel mediated cytotoxic activity against target lung cancer cells [138] . Furthermore, gemcitabine-releasing MSC were able to inhibit the growth of human pancreatic cancer [139] and of squamous cell carcinoma [126] without altering MSC multi-lineage differentiation potential and surface marker expression pattern [140] .

Taking advantage of recombinant lentiviruses, MSC can be modified to over express cytotoxic proteins to kill cancer cells after MSC specific homing. As previously mentioned, this approach could be compliant with GMP rules but its potential therapeutic efficacy was previously tested mainly in vitro and in animal models. Administration of MSC over expressing TRAIL by lentivirus transduction were shown to reduce the growth of pancreatic cancer and sarcomas [141, 142] as well as colorectal carcinoma [143] . Similarly, MSC modified to actively secrete IFN-γ, induced apoptosis in lung tumor cells through caspase-3 activation [144] . Moreover, administration of MSC in which the IFN-β was transduced could lower brain tumor expansion[77] and similarly modified cells could specifically target lung cancer lesions [145] in mice. Interestingly, IL-18 and IFN-β lentiviral overexpression synergically inhibited tumor growth in a rat intracranial glioma model [146] .

MSC were previously transduced by lentiviral or retroviral vectors to induce the expression of herpes simplex virus-thymidine kinase (HSV-TK), an enzyme converting the prodrug ganciclovir to is triphosphate toxic metabolite: After systemic administration of transduced MSC together with ganciclovir, efficient suppression of tumor growth was observed in implanted glioma cells [147] [148] [149] . Retroviral approaches were also used in MSC to induce the expression of cytosine deaminase::uracil phosphoribosyltransferase (CD::UPRT), the enzyme that converts 5-fluorocytosin (5-FC) to an active drug[150]: Such modified MSC actively inhibited prostate cancer growth after intravenous administration in mice. Retroviral MSC modification with HSV-TK, combined with CD::UPRT, synergically counteracted the growth of breast cancer cells and related lung metastases in mice [151] . MSC were also engineered by a lentivirus to play a localized anti-angiogenic role within cancer masses through the secretion of fms-like tyrosine kinase-1; this modification inhibited tumor growth and prolonged survival in a mouse hepatocarcinoma model [152] . After intravenous administration, lentivirus treated MSC co-expressing the angiogenesis inhibitor kringle 5 of human plasminogen and the human sodium-iodide symporter (involved in radioisotope uptake), decreased tumor growth and improved the survival rate of glioblastoma bearing mice [153] . MSC, transduced with the hepatocyte growth factor inhibitor NK4, suppressed the growth of gastric cancer xenografts [154] after systemic administration and this effect was also mediated by impaired intra-tumoral vascularization.

Locally released exosomes from MSC, modified by lentivirus infection to upregulate microRNA (miR) miR-199a or miR-124a, improved hepatocellular carcinoma sensitivity to doxorubicin and eradicated brain cancer in preclinical animal models, respectively [155, 156] .

In addition to lentiviruses, MSC engineering can be performed in GMP compatible conditions by also taking advantage of recombinant adenovirus infection potential. MSC overexpressing the proinflammatory IL-21 were shown in mice to efficiently counteract disseminated B-cell lymphoma through induction of systemic immunity [157] .

Adenoviral transduced TRAIL expression in MSC have shown antitumor effects on esophageal cancer xenografts in mice [158] and, similarly, NK4 modified MSC inhibited liver cancer growth and migration in animal models [159] . MSC transduced to express HSV-TK and TRAIL, induced long-term remission of murine metastatic renal cell carcinoma after three injections (100% survival of tumor-bearing mice) [160] . In comparison, systemic administration of IL-2, IL-12 or IL-18 overexpressing MSC by adenoviral transduction, reduced cancer masses and improved survival after administration in a glioma murine model [161, 162] .

Similarly, injection of MSC in which the expression of HSV-TK was induced by baculovirus-based transduction, inhibited tumor growth and prolonged survival in glioblastoma-bearing mice [163] . Interestingly, in a recent paper, a hybrid baculovirus vector containing key transfection enhancing elements of adeno-associated viruses January 26, 2022

Volume 14 Issue 1 was defined as a promising targeted-delivery vehicle to counteract hypopharyngeal carcinoma [164] .

MSC were shown to be efficient delivery vehicles for oncolytic adenoviruses directed against gliomas [165] . In particular, MSC loaded with the oncolytic adenovirus Delta-24-RGD could eradicate murine glioblastomas [166] and the same approach was applied in healthy dogs to demonstrate its technical feasibility in a more complex model [167] . Oncolytic adenoviruses delivered by MSC efficiently challenged hepatocellular carcinomas with reduced toxicity in healthy liver tissues [168] . Appropriately modified MSC to support viral replication were loaded with an oncolytic adenovirus expressing p14 and p53: Such engineered cells efficiently suppressed prostate cancer progression in mice [169] . Similarly, MSC loaded with a cytolytic adenovirus, additionally expressing TRAIL, efficiently counteracted pancreatic cancer cells in vitro and in xenografted live chick embryos [170] . Administration of MSC carrying an adenoviral oncolytic virus with the addition of a replication defective vector encoding inducible caspase-9, enabled efficient antitumor activity in a non-small-cell lung cancer murine model and improved overall survival [171] . In a clinical trial, involving advanced metastatic neuroblastoma pediatric patients, autologous MSC carrying an oncolytic adenovirus were safely administered and disease stabilization occurred in nearly half of patients [37] .

MSC can be successfully engineered through non-viral vectors achieving transient but sustained gene overexpression. Infusion of MSC overexpressing TRAIL through nonviral vectors were shown to efficiently induce pancreatic or liver cancer cell death [172, 173] . In a murine melanoma model, significant cancer mass reduction was obtained by MSC stably overexpressing IFN-γ through a non-viral method involving PhiC31 recombinase and piggyBac transposase [174] . In mice, intravenously applied MSC transfected to express HSV-TK, reduced primary pancreatic tumor growth and the incidence of metastases[175] and, after tissue specific expression, inhibited expansion of hepatocellular carcinoma cells [176] . In a mouse model, pulmonary cancer nodules were efficiently targeted by MSC induced to express CMV-TK by non-viral methods [177] . Polyethylenimine based polymers were used to transiently engineer MSC with HSV-TK, together with TRAIL: These modified cells were effective in vitro and in vivo against glioma through increased apoptosis and reduced angiogenesis [178] . MSC expressing CDy::UPRT by the same transfection method significantly inhibited in vivo temozolomide resistant glioma tumors [179] as well as 5-fluorouracil resistant colorectal adenocarcinoma cells [180] .

In addition, bone morphogenetic protein 4 overexpression achieved by a non-viral method was demonstrated to induce a reduction of brain tumor cell growth in rats, after intranasal administration and homing within the tumor mass [181] . Interestingly, the same study showed that bone morphogenetic protein 4 engineered MSC treatment significantly improved survival of tumor bearing rats.

Transfected MSC can deliver growth inhibiting miR to tumors: In particular, by direct intercellular communication or locally releasing microvesicles, MSC were demonstrated to transport anti-miR-9 to glioblastoma cells, in turn reversing drug resistance in these cells [182] . Similarly, recent studies have shown that exosomes released from MSC containing elevated amounts of miR-381-3p, miR-34a, miR-193a and miR146a were effective against triple negative breast cancer, non-small cell lung carcinoma and ovarian cancer [183] [184] [185] [186] .

In this review, we briefly reported the biological features of MSC, focusing on cell properties and on mechanisms that could play a crucial role in MSC applications for cancer therapy. The importance of MSC modification to improve their naïve homing properties and to induce a clear cytotoxic behavior was also discussed. Such features are not the only parameters potentially affecting the final clinical outcome related to MSC administration in patients: A thorough discussion regarding this issue is beyond the scope of this review. Briefly, the impact on MSC therapeutic performance mediated by cell origin, expansion protocol, and dosage has not previously been defined [71, 187] . ASC and MSC derived from bone marrow share several biological features and they are both frequently applied in clinical trials. In particular, ASC as well as the stromal vascular fraction derived from adipose tissue, are often used for regenerative medicine purposes [188] [189] [190] , while bone marrow MSC are principally adopted to counteract, among others, graft-versus-host disease [57] or acute renal failure (NCT01275612) in cancer clinical trials. However, the clinical efficacy of bone marrow MSC and of ASC was never compared in the same experimental study. Even if iPSC are to be characterized by great expansion potential[60], such MSC applications in humans are still at very early development stages. Expansion conditions, e.g., cell seeding density [191] or culture medium additives [109] , are known to affect MSC properties but the optimal production approach was not defined in relation to the desired clinical applications. Introduction of automated cell expansion protocols should be strongly encouraged, as it can improve reproducibility of cell growth in GMP environments [192] . Expanded MSC were previously administered in patients in a wide dosage range (from 1 to 4 million cells/kg) by single or multiple administrations [193] . A potentially appropriate minimal effective dose of MSC was previously proposed by analyzing published clinical trial results [187] : The authors suggested that clinical benefits were evident when 100-150 million cells/patient were systemically administered. Significant clinical effects were not registered when less than 70 million cells/patient or, interestingly, over 200 million cells/patient were administered [187] .

In addition to the parameters requiring standardization, as stated above, core MSC properties requiring amelioration to improve their clinical effectiveness in tumor patients are homing potential and the capacity to actively counteract cancer growth. In this review, we reported the efficacy of published preclinical modification protocols aimed at improving such MSC features. Approaches were selected as they were considered potentially suitable for future translation to cell therapy production, in compliance with GMP guidelines. We can hypothesize that both modifications improving homing and cancer killing activity of MSC should be introduced in the same cell therapy product. The definition of comprehensive GMP compliant protocols could allow safe translation to clinical trials in humans.

In conclusion, it is agreed that MSC represent a powerful weapon against cancer but significant efforts are needed to introduce in human clinical trials combinations of relevant MSC modification protocols that were shown to be effective in preclinical studies. The study design of such experimental campaigns in human patients should be highly standardized in order to allow comparison and critical discussion of obtained positive or negative results. 

The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells

Migration of mesenchymal stem cells to tumor xenograft models and in vitro drug delivery by doxorubicin

Drug Loaded Gingival Mesenchymal Stromal Cells (GinPa-MSCs) Inhibit In Vitro Proliferation of Oral Squamous Cell Carcinoma

Nano-loaded human umbilical cord mesenchymal stem cells as targeted carriers of doxorubicin for breast cancer therapy

Tumor tropic delivery of doxorubicin-polymer conjugates using mesenchymal stem cells for glioma therapy

A Nanodrug Consisting Of Doxorubicin And Exosome Derived From Mesenchymal Stem Cells For Osteosarcoma Treatment In Vitro

Anticancer drug-loaded mesenchymal stem cells for targeted cancer therapy

Cell-mediated drug delivery by gingival interdental papilla mesenchymal stromal cells (GinPa-MSCs) loaded with paclitaxel

Effect of canine mesenchymal stromal cells loaded with paclitaxel on growth of canine glioma and human glioblastoma cell lines

Paclitaxel-releasing mesenchymal stromal cells inhibit in vitro proliferation of human mesothelioma cells

Mesenchymal stromal cells primed with Paclitaxel attract and kill leukaemia cells, inhibit angiogenesis and improve survival of leukaemia-bearing mice

Pharmacokinetic-Pharmacodynamic Modeling of Tumor Targeted Drug Delivery Using Nano-Engineered Mesenchymal Stem Cells

Nano-Engineered Mesenchymal Stem Cells Increase Therapeutic Efficacy of Anticancer Drug Through True Active Tumor Targeting

Mesenchymal stem cells loaded with paclitaxelpoly(lactic-co-glycolic acid) nanoparticles for glioma-targeting therapy

Improving Payload Capacity and Anti-Tumor Efficacy of Mesenchymal Stem Cells Using TAT Peptide Functionalized Polymeric Nanoparticles

Gemcitabine-releasing mesenchymal stromal cells inhibit in vitro proliferation of human pancreatic carcinoma cells

Mesenchymal stem cells preserve their stem cell traits after exposure to antimetabolite chemotherapy

MSC-Delivered Soluble TRAIL and Paclitaxel as Novel Combinatory Treatment for Pancreatic Adenocarcinoma

Soluble TRAIL Armed Human MSC As Gene Therapy For Pancreatic Cancer

TRAIL-transduced multipotent mesenchymal stromal cells (TRAIL-MSC) overcome TRAIL resistance in selected CRC cell lines in vitro and in vivo

IFN-γ-secreting-mesenchymal stem cells exert an antitumor effect in vivo via the TRAIL pathway

Effects of mesenchymal stem cells harboring the Interferon-β gene on A549 lung cancer in nude mice

Bone marrow-derived mesenchymal stem cells co-expressing interleukin-18 and interferon-β exhibit potent antitumor effect against intracranial glioma in rats

The Anti-Tumor Effects of Adipose Tissue Mesenchymal Stem Cell Transduced with HSV-Tk Gene on U-87-Driven Brain Tumor

Retroviral vectorproducing mesenchymal stem cells for targeted suicide cancer gene therapy

Cancer gene therapy using mesenchymal stem cells

Adipose tissuederived mesenchymal stem cells expressing prodrug-converting enzyme inhibit human prostate tumor growth

Combined enzyme/prodrug treatment by genetically engineered AT-MSC exerts synergy and inhibits growth of MDA-MB-231 induced lung metastases

Antiangiogenesis gene therapy for hepatocellular carcinoma via systemic injection of mesenchymal stem cells engineered to secrete soluble Flt1

Bone Marrow-Derived Mesenchymal Stem Cell-Mediated Dual-Gene Therapy for Glioblastoma

Mesenchymal stem cell-based NK4 gene therapy in nude mice bearing gastric cancer xenografts

Mesenchymal stem cells as natural biofactories for exosomes carrying miR-124a in the treatment of gliomas

MiR-199a-modified exosomes from adipose tissue-derived mesenchymal stem cells improve hepatocellular carcinoma chemosensitivity through mTOR pathway

IL-21-Expressing Mesenchymal Stem Cells Prevent Lethal B-Cell Lymphoma Through Efficient Delivery of IL-21, Which Redirects the Immune System to Target the Tumor

Human mesenchymal stem cells with adenovirusmediated TRAIL gene transduction have antitumor effects on esophageal cancer cell line Eca-109

The Inhibitory Effect of Mesenchymal Stem Cells with rAd-NK4 on Liver Cancer

Complete regression of metastatic renal cell carcinoma by multiple injections of engineered mesenchymal stem cells expressing dodecameric TRAIL and HSV-TK

Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model

Adenoviral-mediated interleukin-18 expression in mesenchymal stem cells effectively suppresses the growth of glioma in rats

Human embryonic stem cell-derived mesenchymal stem cells as cellular delivery vehicles for prodrug gene therapy of glioblastoma

Human Bone Marrow Mesenchymal Stem Cells Functionalized by Hybrid Baculovirus-Adeno-Associated Viral Vectors for Targeting Hypopharyngeal Carcinoma

Mesenchymal stromal cells for the delivery of oncolytic viruses in gliomas

Human bone marrow-derived mesenchymal stem cells for intravascular delivery of oncolytic adenovirus Delta24-RGD to human gliomas

Endovascular Selective Intra-Arterial Infusion of Mesenchymal Stem Cells Loaded With Delta-24 in a Canine Model

Mesenchymal Stem Cell-Mediated Delivery of an Oncolytic Adenovirus Enhances Antitumor Efficacy in Hepatocellular Carcinoma

Mesenchymal stem cellmediated delivery of therapeutic adenoviral vectors to prostate cancer

Delivery of improved oncolytic adenoviruses by mesenchymal stromal cells for elimination of tumorigenic pancreatic cancer cells

Mesenchymal Stromal Cells for Linked Delivery of Oncolytic and Apoptotic Adenoviruses to Non-small-cell Lung Cancers

TRAILengineered pancreas-derived mesenchymal stem cells: characterization and cytotoxic effects on pancreatic cancer cells

MSC(TRAIL)-mediated HepG2 cell death in direct and indirect co-cultures

PhiC31/PiggyBac modified stromal stem cells: effect of interferon γ and/or tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) on murine melanoma

Targeting tumor stroma using engineered mesenchymal stem cells reduces the growth of pancreatic carcinoma

Selective targeting of genetically engineered mesenchymal stem cells to tumor stroma microenvironments using tissue-specific suicide gene expression suppresses growth of hepatocellular carcinoma

Gene recombinant bone marrow mesenchymal stem cells as a tumor-targeted suicide gene delivery vehicle in pulmonary metastasis therapy using non-viral transfection

Polylysine-modified polyethylenimine polymer can generate genetically engineered mesenchymal stem cells for combinational suicidal gene therapy in glioblastoma

A highly efficient non-viral process for programming mesenchymal stem cells for gene directed enzyme prodrug cancer therapy

Cytotoxic response of 5-fluorouracil-resistant cells to gene-and cell-directed enzyme/prodrug treatment

Nonvirally engineered human adipose mesenchymal stem cells produce BMP4, target brain tumors, and extend survival

Delivery of Functional Anti-miR-9 by Mesenchymal Stem Cell-derived Exosomes to Glioblastoma Multiforme Cells Conferred Chemosensitivity

Exosomal microRNA146a derived from mesenchymal stem cells increases the sensitivity of ovarian cancer cells to docetaxel and taxane via a LAMC2mediated PI3K/Akt axis

Delivery of miR-381-3p Mimic by Mesenchymal Stem Cell-Derived Exosomes Inhibits Triple Negative Breast Cancer Aggressiveness; an In Vitro Study

Exosomes derived from miR-34a-overexpressing mesenchymal stem cells inhibit in vitro tumor growth: A new approach for drug delivery

Bone marrow mesenchymal stem cells-derived exosomal microRNA-193a reduces cisplatin resistance of nonsmall cell lung cancer cells via targeting LRRC1

Trends in mesenchymal stem cell clinical trials 2004-2018: Is efficacy optimal in a narrow dose range?

Stromal vascular fraction: A regenerative reality?

Stromal vascular fraction: A regenerative reality?

Progenitor-enriched adipose tissue transplantation as rescue for breast implant complications

Effects of plating density and culture time on bone marrow stromal cell characteristics

GMP-Compliant Expansion of Clinical-Grade Human Mesenchymal Stromal/Stem Cells Using a Closed Hollow Fiber Bioreactor

Same or not the same?

We are grateful to Dr. Gonzalo Almanza (The Laboratory of Immunology, Department of Medicine and Moores Cancer Center, University of California, San Diego, La Jolla, California) for careful manuscript editing as a native English speaker.